Literature DB >> 17485277

Detection and characterization of circulating and disseminated prostate cancer cells.

Todd M Morgan1, Paul H Lange, Robert L Vessella.   

Abstract

The dissemination of prostate cancer cells to secondary sites appears to be an intermediate step in the formation of tumor metastases. However, the significance of tumor cell dissemination into the blood and bone marrow as well as the characteristics of these cells remains largely unknown. In attempts to correlate the presence of disseminated tumor cells with disease prognosis, studies have utilized a range of molecular and histologic techniques. The results of this research have been largely inconclusive in terms of clinical utility. Nevertheless, they have demonstrated that these cells are detectable and present much more often than would be expected based on the rate of prostate cancer recurrence. Further research has thus begun to focus on the isolation of individual disseminated tumor cells which can then be analyzed with techniques such as gene expression microarrays and comparative genomic hybridization in order to better characterize the cells. This review paper will examine the various methods of detecting disseminated tumor cells in patients with prostate cancer and the results of studies correlating these cells with clinical variables. Additionally, we discuss the isolation and analysis of disseminated cells and examine their potential value in helping to understand the relationship between these cells and tumor metastasis.

Entities:  

Mesh:

Year:  2007        PMID: 17485277     DOI: 10.2741/2290

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  23 in total

Review 1.  The prostate cancer bone marrow niche: more than just 'fertile soil'.

Authors:  Elisabeth A Pedersen; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 2.  The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Authors:  Hung-Ming Lam; Robert L Vessella; Colm Morrissey
Journal:  Drug Discov Today Technol       Date:  2014-03

3.  Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.

Authors:  Todd M Morgan; Paul H Lange; Michael P Porter; Daniel W Lin; William J Ellis; Ian S Gallaher; Robert L Vessella
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 4.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

5.  Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer.

Authors:  Edward W Howard; Steve C L Leung; H F Yuen; Chee Wai Chua; Davy T Lee; K W Chan; Xianghong Wang; Yong Chuan Wong
Journal:  Clin Exp Metastasis       Date:  2008-03-14       Impact factor: 5.150

6.  Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood.

Authors:  Matthias Jost; John R Day; Ryan Slaughter; Theodore D Koreckij; Deanna Gonzales; Martin Kinnunen; Jack Groskopf; Harry G Rittenhouse; Robert L Vessella; Mark A Reynolds
Journal:  Mol Cancer       Date:  2010-07-02       Impact factor: 27.401

Review 7.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

Review 8.  Circulating Tumor Cell Isolation and Analysis.

Authors:  J Zhang; K Chen; Z H Fan
Journal:  Adv Clin Chem       Date:  2016-04-21       Impact factor: 5.394

Review 9.  Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.

Authors:  Robert E Coleman; Theresa A Guise; Allan Lipton; G David Roodman; James R Berenson; Jean-Jacques Body; Brendan F Boyce; Laura M Calvi; Peyman Hadji; Eugene V McCloskey; Fred Saad; Matthew R Smith; Larry J Suva; Russell S Taichman; Robert L Vessella; Katherine N Weilbaecher
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 10.  Targeting bone physiology for the treatment of metastatic prostate cancer.

Authors:  Karen A Autio; Michael J Morris
Journal:  Clin Adv Hematol Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.